N-of-1 CRISPR tri­al ends with a death as non­prof­it digs in­to what hap­pened

Al­most two months af­ter the non­prof­it Cure Rare Dis­ease re­ceived FDA clear­ance to ad­min­is­ter its first-in-hu­man CRISPR ther­a­peu­tic for Duchenne mus­cu­lar dy­s­tro­phy, the non­prof­it an­nounced that the one pa­tient in the tri­al, Ter­ry Hor­gan, the broth­er of the non­prof­it’s founder and CEO, Rich Hor­gan, passed away.

Re­searchers are still try­ing to fig­ure out what ex­act­ly hap­pened with the sin­gle shot CRISPR ther­a­py, the non­prof­it said in a state­ment, and that process may take up to four months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER